Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | RYR2 | Q92736 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9353116 | 0.95 | GAA (0.42) | SMN1; SMN2NPC1RAB9AALDH1A1KMT2A | |
| SCHEMBL22482200 | 0.81 | TDP1 (0.50) | GAARYR2LMNAMAPT | |
| SCHEMBL23673842 | 0.79 | ALDH1A1 (0.52) | SMN1; SMN2RAB9AALDH1A1L3MBTL1HPGD | |
| SCHEMBL17427968 | 0.79 | CA2 (0.45) | KMT2AGAARYR2MEN1 | |
| SCHEMBL30557099 | 0.79 | KMT2A (0.40) | SMN1; SMN2NPC1RAB9AALDH1A1KMT2A | |
| SCHEMBL6772340 | 0.76 | ALDH1A1 (0.42) | SMN1; SMN2NPC1RAB9AALDH1A1KMT2A | |
| SCHEMBL6331933 | 0.75 | MAPT (0.62) | SMN1; SMN2NPC1RAB9AALDH1A1L3MBTL1 | |
| SCHEMBL6039784 | 0.75 | HPGD (0.46) | SMN1; SMN2NPC1RAB9AALDH1A1KMT2A | |
| SCHEMBL27825690 | 0.75 | ALDH1A1 (0.41) | SMN1; SMN2NPC1RAB9AALDH1A1HPGD | |
| SCHEMBL8288869 | 0.74 | ALDH1A1 (0.56) | SMN1; SMN2ALDH1A1GAAHPGDMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 130 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116183763-A9 | Impurity detection method of piracetam injection | 北京星昊盈盛药业有限公司 | 2024-01-05 | — | — | CN | claimed |
| CN-116183763-A | Impurity detection method of piracetam injection | 北京星昊盈盛药业有限公司 | 2023-05-30 | — | — | CN | claimed |
| EP-2643000-A2 | THERAPEUTIC PIPERAZINES | Dart Neuroscience (Cayman) Ltd (KY) | 2013-10-02 | — | — | EP | claimed |
| WO-2012040258-A2 | THERAPEUTIC PIPERAZINES | HELICON THERAPEUTICS, INC. (US) | 2012-03-29 | — | — | WO | claimed |
| US-20110065691-A1 | THERAPEUTIC PIPERAZINES | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2011-03-17 | — | — | US | claimed |
| EP-1863761-A1 | PROCESS FOR PREPARING LEVETIRACETAM | Rubamin Limited (IN) | 2007-12-12 | — | — | EP | claimed |
| WO-2006095362-A1 | PROCESS FOR PREPARING LEVETIRACETAM | RUBAMIN LIMITED (IN) | 2006-09-14 | — | — | WO | claimed |
| CN-117647600-A | Impurity detection method of piracetam injection | 华中药业股份有限公司 | 2024-03-05 | — | — | CN | disclosed |
| CN-116183763-A9 | Impurity detection method of piracetam injection | 北京星昊盈盛药业有限公司 | 2024-01-05 | — | — | CN | disclosed |
| CN-116903485-A | Synthesis method of Piracetam related substance E | 山东玉满坤生物科技有限公司 | 2023-10-20 | — | — | CN | disclosed |
| US-20230270719-A1 | SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-08-31 | — | — | US | disclosed |
| CN-116183763-A | Impurity detection method of piracetam injection | 北京星昊盈盛药业有限公司 | 2023-05-30 | — | — | CN | disclosed |
| US-20230108408-A1 | OXALAMIDE SUBSTITUTED HETEROCYCLIC COMPOUNDS AS MODULATORS OF THE ARYL HYDROCARBON RECEPTOR (AHR) | PHENEX PHARMACEUTICALS AG (DE) | 2023-04-06 | — | — | US | disclosed |
| EP-0457195-B1 | Peptides having endothelin antagonist activity, a process for preparation thereof and pharmaceutical compositions comprising the same | FUJISAWA PHARMACEUTICAL CO (JP) | 1998-04-15 | — | — | EP | disclosed |
| US-5656604-A | HYPOTENSIVE AGENT; ENDOTHELIN ANTAGONIST | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-08-12 | — | — | US | disclosed |
| US-5461157-A | Process for preparing pyrrolidinylacetamide derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1995-10-24 | — | — | US | disclosed |
| US-5430022-A | Endothelin antagonists; hypotensive agents; treatment for angina pectoris, brain disorders, asthma, renal failure | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-07-04 | — | — | US | disclosed |
| US-5284828-A | Hypotensive agents | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 1994-02-08 | — | — | US | disclosed |
| EP-0574952-A1 | Process for preparing 2-oxopyrrolidinylacetamide derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1993-12-22 | — | — | EP | disclosed |
| EP-0457195-A2 | Peptides having endothelin antagonist activity, a process for preparation thereof and pharmaceutical compositions comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-11-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230108408-A1 | OXALAMIDE SUBSTITUTED HETEROCYCLIC COMPOUNDS AS MODULATORS OF THE ARYL HYDROCARBON RECEPTOR (AHR) | AHR, ARNT, HCAR1 | SMN1; SMN2 4621/4885NPC1 2510/4885RAB9A 4689/4885 |
| US-20230270719-A1 | SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF | HMBS, DHFR, HCCS | SMN1; SMN2 4552/4885NPC1 1934/4885RAB9A 3585/4885 |
| US-20110065691-A1 | THERAPEUTIC PIPERAZINES | PDE4A, PDE4B, PDE4D | SMN1; SMN2 923/4885NPC1 1880/4885RAB9A 1524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.